Natera, Inc. (NASDAQ:NTRA) Receives $125.69 Average Target Price from Brokerages

Natera, Inc. (NASDAQ:NTRA - Get Free Report) has earned an average rating of "Buy" from the sixteen research firms that are currently covering the company, MarketBeat.com reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $125.69.

NTRA has been the topic of a number of research reports. Piper Sandler reissued an "overweight" rating and issued a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. Robert W. Baird increased their price objective on shares of Natera from $117.00 to $120.00 and gave the stock an "outperform" rating in a research note on Friday, August 9th. TD Cowen lifted their target price on Natera from $137.00 to $145.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Sanford C. Bernstein increased their price target on shares of Natera from $125.00 to $135.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley boosted their target price on Natera from $125.00 to $132.00 and gave the stock an "overweight" rating in a report on Tuesday, August 13th.

Insider Activity at Natera

In other news, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares of the company's stock, valued at approximately $34,783,235.41. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Jonathan Sheena sold 12,000 shares of the firm's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares of the company's stock, valued at approximately $34,783,235.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 5,583 shares of the business's stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53. Following the completion of the sale, the chief executive officer now directly owns 200,710 shares in the company, valued at approximately $23,866,426.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,164 shares of company stock valued at $6,157,291 over the last ninety days. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Natera

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its holdings in shares of Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company's stock valued at $7,118,000 after acquiring an additional 60,127 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Natera by 15.1% during the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company's stock worth $6,810,000 after acquiring an additional 9,781 shares in the last quarter. Natixis bought a new position in shares of Natera in the first quarter worth $758,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Natera in the second quarter valued at $478,000. Finally, Virtu Financial LLC bought a new stake in shares of Natera during the 1st quarter valued at $707,000. 99.90% of the stock is currently owned by institutional investors.

Natera Trading Up 2.9 %

NASDAQ:NTRA traded up $3.72 during trading hours on Friday, hitting $134.11. The stock had a trading volume of 1,228,911 shares, compared to its average volume of 872,423. The business's 50 day moving average is $124.35 and its 200-day moving average is $113.60. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The company has a market cap of $16.59 billion, a price-to-earnings ratio of -54.74 and a beta of 1.53. Natera has a one year low of $44.77 and a one year high of $134.33.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company's revenue for the quarter was up 58.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.97) earnings per share. Sell-side analysts anticipate that Natera will post -1.96 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.